Breakfast Sponsors

Thursday 17th of november

Breakfast Symposium Sponsored by Evident (Olympus)

8:00 am to 8:45 am

How to care for precious cell lines and how EVIDENT Provi CM20 Incubation Monitoring System Can fit in your workflow:

Dr. Erik Blackwood and his team at the translational cardiovascular research center at the University of Arizona have implemented the CM20 incubation monitoring system to optimize their cell culture monitoring process. They use the system to determine when cell lines are ready for their preclinical trials in rodent models for heart failure. Their approach focuses on identifying small molecule drug-based therapies, but also on gene therapy approaches. The count and confluency calculation capabilities of the CM20 system enable the researchers to monitor the effects of these therapeutics on iPS (induced pluripotent stem) cell lines in real time while the cultures remain safely in the incubator. Utilizing the system’s automated data gathering functions also increases their workflow efficiency.

The CM20 incubation monitoring system provides quantitative data, counts cell number and determines confluency. The data is wirelessly communicated so you can monitor your cultures’ progress without entering the clean room. Measurements are automated using AI, improving on workflow efficiency and yielding quantitative results for your cultures. There is no need to stain or detach the cultures to check their status. The system acquires data from label-free cells, reducing the chance of harm to your cultures. The head scans multiple points in your culture vessel to track the health and confluency of your cell cultures. using constant analysis parameters, helping eliminate variability in analysis results introduced by different operators.

Talk to us to see how the CM20 can fit in your workflow.

friday 18th of november

Breakfast Symposium Sponsored by Murdoch Children's Research Institute

8:00 am to 8:45 am

How MCRI core facilities can facilitate your stem cell research

The Murdoch Children’s Research Institute (MCRI) is internationally recognised for its expertise in pluripotent stem cell technologies and is home to two world-class core facilities that provide tools and resources to Australian stem cell researchers.

Led by Dr Sara Howden, the iPSC Derivation & Gene-editing Facility brings together a team of highly experienced stem cell and molecular biologists to generate standard and custom genetically engineered iPSCs on a cost-recovery basis. A unique feature of our facility is the use of a streamlined one-step gene-editing/reprogramming methodology for extremely rapid and efficient generation of clonally derived gene-edited iPSC lines from primary patient fibroblasts or blood. We liaise with researchers to devise the ideal strategy for achieving optimal gene-editing outcomes based upon the ever-expanding number of gene-editing tools available.

The Disease Modelling Facility (DMF), led by Dr Hidalgo Gonzalez, uses cutting edge technologies and stem cell-derived tissues to develop robust pipelines for human targeted drug discovery. By modelling a ‘disease in a dish’, we are able to understand disease mechanism-of-action and test clinically validated drug targets. We design automated high content-high throughput, drug screening of compounds using human derived cells and organoids. The DMF aim is to accelerated human target identification using advance human models generated from pluripotent stem cells.